Search | WHO COVID-19 Research Database

1.

Post-exposure prophylaxis of COVID-19: results of double-blind, placebo-controlled, multicenter clinical study evaluation of efficacy and safety of double-stranded sodium salt RNA drug

Balykova, L. A.; Radaeva, O. A.; Zaslavskaya, K. Y.; Taganov, A. V.; Bely, P. A.; Zakharov, K. A.; Popova, V. V.; Chudinovskikh, T. I.; Teplykh, S. V.; Balaban, I. V.; Kozlov, R. S.; Kirichenko, N. V.; Simakina, E. N.; Koryanova, K. N.; Pushkar, D. Y..

Pharmacy & Pharmacology-Farmatsiya I Farmakologiya ; 11(1):72-88, 2023.

Article in English | Web of Science | ID: covidwho-20232876

ABSTRACT

The aim of the study was to evaluate the efficacy and safety of an RNA double-stranded sodium salt drug, a lyophilisate for a solution preparation for an intramuscular and subcutaneous administration, as a means of post-exposure COVID-19 prophylaxis in comparison with placebo.Material and methods. A double-blind, placebo-controlled, multicenter, randomized phase III clinical trial was conducted to evaluate the efficacy and safety of a double-stranded sodium salt RNA drug (RADAM IN (R) VIRO), a lyophilisate for preparing a solution for intramuscular and subcutaneous administration as a means of post-exposure prophylaxis of COVID-19. The study was conducted in 10 research centers in the Russian Federation from May 31, 2022 to January 17, 2023. The study included men and women aged =18 years who cohabitate with a person with a documented COVID-19 diagnosis and do not have symptoms characteristic of COVID-19. At the randomization stage, the subjects were assigned to one of two groups: group 1 (n=400) received a study drug RADAM IN (R) VIRO 5 mg (1 vial) intramuscularly once a day;group 2 (n=400) received placebo 1 vial intramuscularly once a day. The total duration of the study for each subject was no more than 30 days.Results. By day 10-11, in the double-stranded sodium salt RNA drug group, the proportion of the subjects with confirmed COVID-19 and at least 1 symptom characteristic of COVID-19 was 5.76% (23/399), and in the placebo group - 11.03% (44/399). The difference in proportions between the study drug and placebo groups was 0.0526 (5.26%), the 95% confidence interval (CI) for the difference in proportions between the groups was [0.0123;0.0937]). More than 94% of single-dose subjects did not become infected with COVID-19 with any symptoms during the 11 days of the follow-up. As a result of a comparative analysis, it was shown that the infection frequency in the study drug group was statistically significantly (almost twice) less than in the comparison group, which indicates a high efficiency and expediency of using the double-stranded sodium salt RNA drug as a means of the post-exposure COVID-19 prophylaxis.Conclusion. Thus, regardless of the vaccination availability, the effectiveness and feasibility of using the study double -stranded sodium salt RNA drug as a means of the post-exposure COVID-19 prophylaxis was demonstrated not only in medical institutions (outpatient clinics and hospitals), but also in caregivers and/or the persons in contact with COVID-19 patients. The situation was the same in the organizations and enterprises in case of evolution of a mass infection threat and the availability of appropriate medical personnels.

2.

International register “dynamics analysis of comorbidities in sars-cov-2 survivors” (Aktiv sars-cov-2): Analysis of predictors of short-term adverse outcomes in covid-19

Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Rebrov, A. P.; Tereshchenko, S. N.; Chesnikova, A. I.; Hayrapetyan, H. G.; Babin, A. P.; Bakulin, I. G.; Bakulina, N. V.; Balykova, L. A.; Blagonravova, A. S.; Boldina, M. V.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigorieva, N. U.; Gubareva, I. V.; Demko, I. V.; Evzerikhina, A. V.; Zharkov, A. V.; Kamilova, U. K.; Kim, Z. F.; Kuznetsova, T. Yu, Lareva, N. V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Petrova, M. M.; Pochinka, I. G.; Protasov, K. V.; Protsenko, D. N.; Ruzanov, D. Yu, Sayganov, S. A.; Sarybaev, A. Sh, Selezneva, N. M.; Sugraliev, A. B.; Fomin, I. V.; Khlynova, O. V.; Chizhova, O. Yu, Shaposhnik, I. I.; Sсhukarev, D. A.; Abdrahmanova, A. K.; Avetisian, S. A.; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch, Alieva, M. K.; Aparkina, A. V.; Aruslanova, O. R.; Ashina, E. Yu, Badina, O. Y.; Barisheva, O. Yu, Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Vezikova, N. N.; Verbitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Gаlova, E. A.; Genkel, V. V.; Gorshenina, E. I.; Gostishev, R. V.; Grigorieva, E. V.; Gubareva, E. Yu, Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu, Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K. E.; Ermilova, A. N.; Zheldybayeva, A. E.; Zarechnova, N. V.; Ivanova, S. Yu, Ivanchenko, E. Yu, Ilina, M. V.; Kazakovtseva, M. V.; Kazymova, E. V.; Kalinina, Y. S.; Kamardina, N. A.; Karachenova, A. M.; Karetnikov, I. A.; Karoli, N. A.; Karpov, O. V.; Karsiev, M. Kh, Кaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Z. B.; Kerimova, A. Sh, Kim, E. S.; Kiseleva, N. V.; Klimenko, D. A.; Klimova, A. V.; Kovalishena, O. V.; Kolmakova, E. V.; Kolchinskaya, T. P.; Kolyadich, M. I.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu, Konstantinova, E. A.; Kordukova, V. A.; Koroleva, E. V.; Kraposhina, A. Yu, Kriukova, T. V.; Kuznetsova, A. S.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kulchoroeva, C. K.; Kuprina, T. V.; Kouranova, I. M.; Kurenkova, L. V.; Kurchugina, N. Yu, Kushubakova, N. A.; Levankova, V. I.; Levin, M. E.; Lyubavina, N. A.; Magdeyeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Maripov, A. M.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F. N.; Muradyan, R. G.; Musaelian, S. N.; Nikitina, N. M.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Y. M.; Omurzakova, N. A.; Ospanova, S. O.; Pahomova, E. V.; Petrov, L. D.; Plastinina, S. S.; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Pudova, I. A.; Rakov, N. A.; Rakhimov, A. N.; Rozanova, N. A.; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, I. A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D. R.; Titojkina, Y. V.; Tikhonova, E. P.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Tulichev, A. A.; Tupitsin, D. I.; Tursunova, A. T.; Ulanova, N. D.; Fatenkov, O. V.; Fedorishina, O. V.; Fil, T. S.; Fomina, I. Yu, Fominova, I. S.; Frolova, I. A.; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, M. B.; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, O. A.; Sheshina, T. V.; Shishkina, E. A.; Shishkov, K. Yu, Sherbakov, S. Y.; Yausheva, E. A..

Russian Journal of Cardiology ; 26(4):116-131, 2021.

Article in Russian | EMBASE | ID: covidwho-1488885

ABSTRACT

The international AKTIV register presents a detailed description of out-and inpatients with COVID-19 in the Eurasian region. It was found that hospitalized patients had more comorbidities. In addition, these patients were older and there were more men than among outpatients. Among the traditional risk factors, obesity and hypertension had a significant negative effect on prognosis, which was more significant for patients 60 years of age and older. Among comorbidities, CVDs had the maximum negative effect on prognosis, and this effect was more significant for patients 60 years of age and older. Among other comorbidities, type 2 and 1 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, cancer and anemia had a negative impact on the prognosis. This effect was also more significant (with the exception of type 1 diabetes) for patients 60 years and older. The death risk in patients with COVID-19 depended on the severity and type of multimorbidity. Clusters of diseases typical for deceased patients were identified and their impact on prognosis was determined. The most unfavorable was a cluster of 4 diseases, including hypertension, coronary artery disease, heart failure, and diabetes mellitus. The data obtained should be taken into account when planning measures for prevention (vaccination priority groups), treatment and rehabilitation of COVID-19 survivors.

3.

International register “dynamics analysis of comorbidities in sars-cov-2 survivors” (Aktiv) and the register “analysis of hospitalizations of comorbid patients infected during the second wave of sars-cov-2 outbreak” (aktiv 2)

Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Rebrov, A. P.; Tereshchenko, S. N.; Che Snikova, A. I.; Hayrapetyan, H. G.; Babin, A. P.; Bakulin, I. G.; Bakulina, N. V.; Balykova, L. A.; Blagonravova, A. S.; Boldina, M. V.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigorieva, N. U.; Gubareva, I. V.; Demko, I. V.; Evzerikhina, A. V.; Zharkov, A. V.; Kamilova, U. K.; Kim, Z. F.; Kuznetsova, T. Yu, Lareva, N. V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Petrova, M. M.; Pochinka, I. G.; Protasov, K. V.; Protsenko, D. N.; Ruzanov, D. Yu, Sayganov, S. A.; Sarybaev, A. Sh, Selezneva, N. M.; Sugraliev, A. B.; Fomin, I. V.; Khlynova, O. V.; Chizhova, O. Yu, Shaposhnik, I. I.; Sсhukarev, D. A.; Abdrahmanova, A. K.; Avetisian, S. A.; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch, Alieva, M. K.; Aparkina, A. V.; Aruslanova, O. R.; Ashina, E. Yu, Badina, O. Y.; Barisheva, O. Yu, Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Vezikova, N. N.; Ver Bitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Gаlova, E. A.; Genkel, V. V.; Gorshenina, E. I.; Gostishev, R. V.; Grigorieva, E. V.; Gubareva, E. Yu, Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu, Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K. E.; Ermilova, A. N.; Zheldybayeva, A. E.; Zarechnova, N. V.; Ivanova, S. Yu, Ivanchenko, E. Yu, Ilina, M. V.; Kazakovtseva, M. V.; Kazymova, E. V.; Kalinina, Yu S.; Kamardina, N. A.; Karachenova, A. M.; Karetnikov, I. A.; Karoli, N. A.; Karpov, O. V.; Karsiev, M. Kh, Кaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Zh B.; Kerimova, A. Sh, Kim, E. S.; Kiseleva, N. V.; Klimenko, D. A.; Klimova, A. V.; Kovalishena, O. V.; Kolmakova, E. V.; Kolchinskaya, T. P.; Kolyadich, M. I.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu, Konstantinova, E. A.; Kordukova, V. A.; Koroleva, E. V.; Kraposhina, A. Yu, Kriukova, T. V.; Kuznetsova, A. S.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kulchoroeva, Ch K.; Kuprina, T. V.; Kouranova, I. M.; Kurenkova, L. V.; Kurchugina, N. Yu, Kushubakova, N. A.; Levankova, V. I.; Levin, M. E.; Lyubavina, N. A.; Magdeyeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Maripov, A. M.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F. N.; Muradyan, R. G.; Musaelian, Sh N.; Nikitina, N. M.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Yu M.; Omurzakova, N. A.; Ospanova, Sh O.; Pahomova, E. V.; Petrov, L. D.; Plastinina, S. S.; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Pudova, I. A.; Rakov, N. A.; Rakhimov, A. N.; Rozanova, N. A.; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, I. A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D. R.; Titojkina, Y. V.; Tikhonova, E. P.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Tulichev, A. A.; Tupitsin, D. I.; Tursunova, A. T.; Tiurin, A. A.; Ulanova, N. D.; Fatenkov, O. V.; Fedorishina, O. V.; Fil, T. S.; Fomina, I. Yu, Fominova, I. S.; Frolova, I. A.; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, M. B.; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, O. A.; Sheshina, T. V.; Shishkina, E. A.; Shishkov, K. Yu, Sherbakov, S. Y.; Yausheva, E. A..

Russian Journal of Cardiology ; 26(3):102-113, 2021.

Article in Russian | EMBASE | ID: covidwho-1488882

ABSTRACT

The organizer of the registers “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV) and “Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2 outbreak” (AKTIV 2) is the Eurasian Association of Therapists (EAT). Currently, there are no clinical registries in the Eurasian region designed to collect and analyze information on long-term outcomes of COVID-19 survivors with comorbid conditions. The aim of the register is to assess the impact of a novel coronavirus infection on long-term course of chronic non-communicable diseases 3, 6, 12 months after recovery, as well as to obtain information on the effect of comorbidity on the severity of COVID-19. Analysis of hospitalized patients of a possible second wave is planned for register “AKTIV 2”. To achieve this goal, the register will include men and women over 18 years of age diagnosed with COVID-19 who are treated in a hospital or in outpatient basis. The register includes 25 centers in 5 federal districts of the Russian Federation, centers in the Republic of Armenia, the Republic of Kazakhstan, the Republic of Kyrgyzstan, the Republic of Belarus, the Republic of Moldova, and the Republic of Uzbekistan. The estimated capacity of the register is 5400 patients.

4.

INTERNATIONAL REGISTER “DYNAMICS ANALYSIS OF COMORBIDITIES IN SARS-COV-2 SURVIVORS” (AKTIV SARS-COV-2): ANALYSIS OF 1,000 PATIENTS

Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Tereshchenko, S. N.; Rebrov, A. P.; Chesnikova, A. I.; Fomin, I. V.; Grigorieva, N. U.; Boldina, M. V.; Vaisberg, A. R.; Blagonravova, A. S.; Makarova, E. V.; Shaposhnik, I. I.; Kuznetsova, T. Yu, Malchikova, S. V.; Protsenko, D. N.; Evzerikhina, A. V.; Petrova, M. M.; Demko, I. V.; Safonov, D. V.; Hayrapetyan, H. G.; Galyavich, A. S.; Kim, Z. F.; Sugraliev, A. B.; Nedogoda, S. V.; Tsoma, V. V.; Sayganov, S. A.; Gomonova, V. V.; Gubareva, I. V.; Sarybaev, A. Sh, Koroleva, E. V.; Vilkova, O. E.; Fomina, I. Y.; Pudova, I. A.; Soloveva, D. V.; Kiseleva, N. V.; Zelyaeva, N. V.; Kouranova, I. M.; Pogrebetskaya, V. A.; Muradova, F. N.; Badina, O. Y.; Kovalishena, O. V.; Galova, E. A.; Plastinina, S. S.; Lyubavina, N. A.; Vezikova, N. N.; Levankova, V. I.; Ivanova, S. Yu, Ermilova, A. N.; Muradyan, R. G.; Gostishev, R. V.; Tikhonova, E. P.; Kuzmina, T. Y.; Soloveva, I. A.; Kraposhina, A. Yu, Kolyadich, M. I.; Kolchinskaya, T. P.; Genkel, V. V.; Kuznetsova, A. S.; Kazakovtseva, M. V.; Odegova, A. A.; Chudinovskikh, T. I.; Baramzina, S. V.; Rozanova, N. A.; Kerimova, A. Sh, Krivosheina, N. A.; Chukhlova, S. Y.; Levchenko, A. A.; Avoyan, H. G.; Azarian, K. K.; Musaelian, Sh N.; Avetisian, S. A.; Levin, M. E.; Karpov, O. V.; Sokhova, F. M.; Burygina, L. A.; Sheshina, T. V.; Tiurin, A. A.; Dolgikh, O. Yu, Kazymova, E. V.; Konstantinov, D. Yu, Chumakova, O. A.; Kondriakova, O. V.; Shishkov, K. Yu, Fil, T. S.; Prokofeva, N. A.; Konoval, M. P.; Simonov, A. A.; Bitieva, A. M.; Trostianetckaia, N. A.; Cholponbaeva, M. B.; Kerimbekova, Zh B.; Duyshobayev, M. Y.; Akunov, A. Ch, Kushubakova, N. A.; Melnikov, E. S.; Kim, E. S.; Sherbakov, S. Y.; Trofimov, D. A.; Evdokimov, D. S.; Ayipova, D. A.; Duvanov, I. A.; Abdrakhmanova, A. K.; Aimakhanova, G. T.; Ospanova, Sh O.; Dabylova, G. M.; Tursunova, A. T.; Kaskaeva, D. S.; Tulichev, A. A.; Ashina, E. Yu, Kordukova, V. A.; Barisheva, O. Yu, Egorova, K. E.; Varlamova, D. D.; Kuprina, T. V.; Pakhomova, E. V.; Kurchugina, N. Yu, Frolova, I. A.; Mazalov, K. V.; Subbotin, A. K.; Kamardina, N. A.; Zarechnova, N. V.; Mamutova, E. M.; Smirnova, L. A.; Klimova, A. V.; Shakhgildyan, L. D.; Tokmin, D. S.; Tupitsin, D. I.; Kriukova, T. V.; Rakov, N. A.; Polyakov, D. S..

Russian Journal of Cardiology ; 25(11):98-107, 2020.

Article in Russian | Russian Science Citation Index | ID: covidwho-1094455

ABSTRACT

COVID-19 is a severe infection with high mortality. The concept of the disease has been shaped to a greater extent on the basis of large registers from the USA, Spain, Italy, and China. However, there is no information on the disease characteristics in Caucasian patients. Therefore, we created an international register with the estimated capacity of 5,000 patients - Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (AKTIV SARS-CoV-2), which brought together professionals from the Russian Federation, Republic of Armenia, Republic of Kazakhstan, and Kyrgyz Republic. The article presents the first analysis of the register involving 1,003 patients. It was shown that the most significant difference of the Caucasian population was the higher effect of multimorbidity on the mortality risk vs other registers. More pronounced effect on mortality of such diseases as diabetes, obesity, hypertension, chronic kidney disease, and age over 60 years was also revealed. COVID-19 - тяжелое инфекционное заболевание с высоким риском летального исхода. Представление о болезни во многом сформировано на основании крупных регистров, выполненных в США, Испании, Италии, КНР. Однако к настоящему времени нет данных по особенностям протекания болезни у пациентов евроазиатского региона. В связи с этим был создан международный регистр, расчетная мощность которого составляет 5000 пациентов, “Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS-CoV-2” (AКТИВ SARS-CoV-2), работа в котором объединила специалистов Российской Федерации, Республики Армения, Республики Казахстан и Кыргызской Республики. В статье представлен первый анализ регистра, который включил данные 1003 пациентов. Показано, что самым значимым отличием евроазиатской популяции пациентов оказалось гораздо большее влияние полиморбидности на риск летального исхода в сравнении с другими регистрами, а также более выраженное влияние на риск летального исхода в евроазиатской популяции таких заболеваний, как сахарный диабет, ожирение, артериальная гипертензия, хроническая болезнь почек и возраста старше 60 лет.

5.

[International register "Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients (ACTIV SARS-CoV-2)"]

Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Tereshchenko, S. N.; Rebrov, A. P.; Chesnikova, A. I.; Fomin, I. V.; Grigorieva, N. U.; Boldina, V. M.; Vaisberg, A. R.; Blagonravova, A. S.; Makarova, E. V.; Shaposhnik, II, Kuznetsova, T. Y.; Malchikova, S. V.; Protsenko, D. N.; Evzerikhina, A. V.; Petrova, M. M.; Demko, I. V.; Saphonov, D. V.; Hayrapetyan, H. G.; Galyavich, A. S.; Kim, Z. F.; Sugraliev, A. B.; Nedogoda, S. V.; Tsoma, V. V.; Sayganov, S. A.; Gomonova, V. V.; Gubareva, I. V.; Sarybaev, A. S.; Ruzanau, D. Y.; Majseenko, V. I.; Babin, A. P.; Kamilova, U. K.; Koroleva, E. V.; Vilkova, O. E.; Fomina, I. Y.; Pudova, I. A.; Soloveva, D. V.; Doshchannikov, D. A.; Kiseleva, N. V.; Zelyaeva, N. V.; Kouranova, I. M.; Pogrebetskaya, V. A.; Muradova, F. N.; Badina, O. Y.; Kovalishena, O. V.; Gsmall a, Cyrilliclova A. E.; Plastinina, S. S.; Grigorovich, M. S.; Lyubavina, N. A.; Vezikova, N. N.; Levankova, V. I.; Ivanova, S. Y.; Ermilova, A. N.; Muradyan, R. G.; Gostishev, R. V.; Tikhonova, E. P.; Kuzmina, T. Y.; Soloveva, I. A.; Kraposhina, A. Y.; Kolyadich, M. I.; Kolchinskaya, T. P.; Genkel, V. V.; Kuznetsova, A. S.; Kazakovtseva, M. V.; Odegova, A. A.; Chudinovskikh, T. I.; Baramzina, S. V.; Rozanova, N. A.; Kerimova, A. S.; Krivosheina, N. A.; Chukhlova, S. Y.; Levchenko, A. A.; Avoyan, H. G.; Azarian, K. K.; Musaelian, S. N.; Avetisian, S. A.; Levin, M. E.; Karpov, O. V.; Sokhova, F. M.; Burygina, L. A.; Sheshina, T. V.; Tiurin, A. A.; Dolgikh, O. Y.; Kazymova, E. V.; Konstantinov, D. Y.; Chumakova, O. A.; Kondriakova, O. V.; Shishkov, K. Y.; Fil, S. T.; Prokofeva, N. A.; Konoval, M. P.; Simonov, A. A.; Bitieva, A. M.; Trostianetckaia, N. A.; Cholponbaeva, M. B.; Kerimbekova, Z. B.; Duyshobayev, M. Y.; Akunov, A. C.; Kushubakova, N. A.; Melnikov, E. S.; Kim, E. S.; Sherbakov, S. Y.; Trofimov, D. A.; Evdokimov, D. S.; Ayipova, D. A.; Duvanov, I. A.; Abdrahmanova, A. K.; Aimakhanova, G. T.; Ospanova, S. O.; Gaukhar, M. D.; Tursunova, A. T.; Kaskaeva, D. S.; Tulichev, A. A.; Ashina, E. Y.; Kordukova, V. A.; Barisheva, O. Y.; Egorova, K. E.; Varlamova, D. D.; Kuprina, T. V.; Pahomova, E. V.; Kurchugina, N. Y.; Frolova, I. A.; Mazalov, K. V.; Subbotin, A. K.; Kamardina, N. A.; Zarechnova, N. V.; Mamutova, E. M.; Smirnova, L. A.; Klimova, A. V.; Shakhgildyan, L. D.; Tokmin, D. S.; Tupitsin, D. I.; Kriukova, T. V.; Polyakov, D. S.; Karoli, N. A.; Grigorieva, E. V.; Magdeyeva, N. A.; Aparkina, A. V.; Nikitina, N. M.; Petrov, L. D.; Budu, A. M.; Rasulova, Z. D.; Tagayeva, D. R.; Fatenkov, O. V.; Gubareva, E. Y.; Demchenko, A. I.; Klimenko, D. A.; Omarova, Y. V.; Serikbolkyzy, S.; Zheldybayeva, A. E..

Kardiologiia ; 60(11):30-34, 2021.

Article in Russian | Scopus | ID: covidwho-1070011

ABSTRACT

.

ABSTRACT

ABSTRACT

ABSTRACT

ABSTRACT

ABSTRACT

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL